Sonova Holding AG (SWX:SOON)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 10.62B -26.3% |
| Revenue (ttm) | 3.85B +3.8% |
| Net Income | 520.40M -7.8% |
| EPS | 8.71 -7.8% |
| Shares Out | 59.61M |
| PE Ratio | 20.45 |
| Forward PE | 17.62 |
| Dividend | 4.40 (2.47%) |
| Ex-Dividend Date | Jun 13, 2025 |
| Volume | 41,001 |
| Average Volume | 161,806 |
| Open | 178.00 |
| Previous Close | 178.20 |
| Day's Range | 175.40 - 178.60 |
| 52-Week Range | 163.00 - 283.50 |
| Beta | 1.07 |
| RSI | 44.48 |
| Earnings Date | May 18, 2026 |
About Sonova Holding AG
Sonova Holding AG manufactures and sells hearing care solutions for children and adults in Switzerland, the United States, rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segment engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Ha... [Read more]
Financial Performance
In fiscal year 2025, Sonova Holding AG's revenue was 3.87 billion, an increase of 6.58% compared to the previous year's 3.63 billion. Earnings were 540.50 million, a decrease of -10.07%.
Financial StatementsNews
Sonova price target lowered to CHF 172 from CHF 184 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Sonova (SONVY) to CHF 172 from CHF 184 and keeps an Underweight rating on the shares.
Sonova upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Sonova (SONVY) to Neutral from Underweight with a price target of CHF 163, up from CHF 158. The firm sees the end of negative estimate revisions for Sonova.
Sonova price target lowered to CHF 188 from CHF 237 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Sonova (SONVY) to CHF 188 from CHF 237 and keeps a Hold rating on the shares. Published first on…
Sonova price target lowered to CHF 158 from CHF 176 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Sonova (SONVY) to CHF 158 from CHF 176 and keeps an Underweight rating on the shares.
Sonova downgraded to Underperform from Hold at Jefferies
Jefferies downgraded Sonova (SONVY) to Underperform from Hold with a price target of CHF 155, down from CHF 215. The stock’s valuation “remains rich” given the company’s slowing growth prospects,…
Sonova upgraded to Outperform from Underperform at BNP Paribas
BNP Paribas upgraded Sonova (SONVY) to Outperform from Underperform with a CHF 230 price target
Sonova expects FY revenue at lower end of target range, CEO says in interview
Sonova's full year revenue will come at the lower end of its 2025/2026 forecast range for growth of 5% to 9%, hearing-aid maker CEO Eric Bernard said in an interview published on Friday.
Sonova initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Sonova (SONVY) with an Outperform rating and CHF 250 price target The firm sees the company’s “market leadership positioning and technological differentiation” drivin...
Sonova price target lowered to CHF 176 from CHF 195 at JPMorgan
JPMorgan lowered the firm’s price target on Sonova (SONVY) to CHF 176 from CHF 195 and keeps an Underweight rating on the shares.
Sonova price target lowered to CHF 237 from CHF 248 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sonova (SONVY) to CHF 237 from CHF 248 and keeps a Hold rating on the shares.
Sonova re-initiated with an Underperform at BNP Paribas Exane
BNP Paribas Exane re-initiated coverage of Sonova (SONVY) with an Underperform rating and CHF 195 price target The firm cites the company’s “weak” end markets and intense competition for the…
Sonova upgraded to Neutral from Sell at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Issie Kirby upgraded Sonova (SONVY) to Neutral from Sell with a price target of CHF 215, up from CHF 210. The firm says the weaker…
Sonova price target raised to CHF 195 from CHF 189 at JPMorgan
JPMorgan raised the firm’s price target on Sonova (SONVY) to CHF 195 from CHF 189 and keeps an Underweight rating on the shares.
Sonova upgraded to Outperform from Market Perform at Bernstein
Bernstein analyst Susannah Ludwig upgraded Sonova (SONVY) to Outperform from Market Perform with a price target of CHF 278, up from CHF 270. The firm says the recent selloff is…
Sonova downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Hassan Al-Wakeel downgraded Sonova (SONVY) to Underweight from Equal Weight with a price target of CHF 225, down from CHF 275. The firm believes the stock’s valuation remains…
Sonova downgraded to Underperform from Outperform at BNP Paribas Exane
BNP Paribas Exane downgraded Sonova (SONVY) to Underperform from Outperform with a CHF 215 price target The company’s product momentum tailwinds are easing, the analyst tells investors in a research…
Sonova upgraded to Hold from Reduce at Kepler Cheuvreux
Kepler Cheuvreux upgraded Sonova (SONVY) to Hold from Reduce with a price target of CHF 255, up from CHF 220. The firm expects a solid year for the company owning…
Sonova price target lowered to CHF 235 from CHF 244 at Citi
Citi analyst Giang Nguyen lowered the firm’s price target on Sonova (SONVY) to CHF 235 from CHF 244 and keeps a Sell rating on the shares.
Sonova downgraded to Sell from Neutral at Redburn Atlantic
Redburn Atlantic analyst Issie Kirby downgraded Sonova (SONVY) to Sell from Neutral with a CHF 225 price target
Sonova downgraded to Hold from Buy at HSBC
HSBC analyst Shubhangi Gupta downgraded Sonova (SONVY) to Hold from Buy with a CHF 285 price target
Sonova price target lowered to CHF 189 from CHF 224 at JPMorgan
JPMorgan lowered the firm’s price target on Sonova (SONVY) to CHF 189 from CHF 224 and keeps an Underweight rating on the shares.
Sonova Shares Jump on Sales Beat, CEO Change
The stock rose after the company said its current chief would be replaced by the former CEO of hearing aids manufacturer WS Audiology.
Launch costs hit Sonova's profit, as it bets on new product with AI tech
Sonova reported half-year core profit below market expectations on Tuesday, hit by costs related to the launch of its new AI-boosted hearing device which it is betting on to regain market share.
Swiss hearing aid maker Sonova resumes supplying Costco, source says
Swiss hearing aid maker Sonova is resuming supplies to Costco , a source with knowledge of the matter told Reuters on Monday.